Cargando…

Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes. Phenotype 1 is a moderate (but not clinically severe) drop in platelet coun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slingsby, Martina H. Lundberg, Vijey, Prakrith, Tsai, I-Ting, Roweth, Harvey, Couldwell, Genevieve, Wilkie, Adrian R., Gaus, Hans, Goolsby, Jazana M., Okazaki, Ross, Terkovich, Brooke E., Semple, John W., Thon, Jonathan N., Henry, Scott P., Narayanan, Padmakumar, Italiano, Joseph E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804562/ https://www.ncbi.nlm.nih.gov/pubmed/33567808 http://dx.doi.org/10.3324/haematol.2020.260059

Ejemplares similares

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
por: Crooke, Stanley T., et al.
Publicado: (2017)

Effective Exon Skipping and Dystrophin Restoration by 2′-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice
por: Yang, Lu, et al.
Publicado: (2013)

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
por: Crooke, Stanley T, et al.
Publicado: (2016)

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Platelet Activation by Antisense Oligonucleotides (ASOs) in the Göttingen Minipig, including an Evaluation of Glycoprotein VI (GPVI) and Platelet Factor 4 (PF4) Ontogeny
por: Valenzuela, Allan, et al.
Publicado: (2023)

The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
por: Crooke, Stanley T., et al.
Publicado: (2018)

Efficient Synthesis of 2’‐O‐Methoxyethyl Oligonucleotide‐Cationic Peptide Conjugates
por: Halloy, François, et al.
Publicado: (2021)

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications
por: Yu, Rosie Z, et al.
Publicado: (2015)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

Lessons to learn from tumor-educated platelets
por: Roweth, Harvey G., et al.
Publicado: (2021)

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
por: Watts, Lynnetta M., et al.
Publicado: (2020)

High-Intensity Exercise Training Improves Basal Platelet Prostacyclin Sensitivity and Potentiates the Response to Dual Anti-Platelet Therapy in Postmenopausal Women
por: Wickham, Kate A., et al.
Publicado: (2022)

Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro
por: Guo, Qiuchen, et al.
Publicado: (2022)

Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
por: Chappell, Alfred E, et al.
Publicado: (2020)

T granules in human platelets function in TLR9 organization and signaling
por: Thon, Jonathan N., et al.
Publicado: (2012)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
por: Yu, Rosie Z., et al.
Publicado: (2017)

Peptide Conjugates of a 2′-O-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes
por: Hill, Alyssa C., et al.
Publicado: (2023)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

N-(2-Methoxyethyl)phthalimide
por: Sim, Yoke Leng, et al.
Publicado: (2008)

Cytoskeletal mechanics of proplatelet maturation and platelet release
por: Thon, Jonathan N., et al.
Publicado: (2010)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Shear Stress Promotes Platelet Surface Desialylation, Platelet Count Drop, and Microvesiculation: Do Platelets Need to be Sugar-Coated?
por: Roka-Moiia, Yana, et al.
Publicado: (2022)

Elucidation of the Biotransformation Pathways of a Galnac(3)-conjugated Antisense Oligonucleotide in Rats and Monkeys
por: Shemesh, Colby S, et al.
Publicado: (2016)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Pharmacological actions of nobiletin in the modulation of platelet function
por: Vaiyapuri, Sakthivel, et al.
Publicado: (2015)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ru81pjf07lusgro18b754a8tqu